Pharsight

Drugs that contain Bupivacaine; Meloxicam

1. Zynrelef Kit patents expiration

ZYNRELEF KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744163 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(10 years from now)

US9913909 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(10 years from now)

US11253504 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(10 years from now)

US9592227 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(10 years from now)

US10398686 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(10 years from now)

US10632199 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(11 years from now)

US10898575 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(11 years from now)

US11083797 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(11 years from now)

US11083730 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(11 years from now)

US10980886 HERON THERAPS INC Compositions of a polyorthoester and an organic acid excipient
Apr, 2035

(11 years from now)

US11413350 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(11 years from now)

US9694079 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(11 years from now)

US9801945 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(11 years from now)

US10213510 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(11 years from now)

US10098957 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(11 years from now)

US11844837 HERON THERAPS INC Compositions of a polyorthoester and an organic acid excipient
Apr, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 12, 2024

Market Authorisation Date: 12 May, 2021

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarti...

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

More Information on Dosage

ZYNRELEF KIT family patents

Family Patents